Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM4B | O94953 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670689 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2ADORA2ALMNATSHRSLC6A4 | |
| SCHEMBL9127861 | 0.69 | — | — | |
| SCHEMBL906665 | 0.68 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1PDPK1KDM4AKDM4B | |
| SCHEMBL9049460 | 0.67 | ADORA2A (0.55) | SMN1; SMN2ADORA2ALMNATSHRSLC6A4 | |
| SCHEMBL1221476 | 0.67 | PNP (0.47) | SMN1; SMN2ADORA2ALMNATSHRSLC6A4 | |
| SCHEMBL4564464 | 0.66 | HSD17B10 (0.50) | SMN1; SMN2ADORA2ALMNATSHRSLC6A4 | |
| SCHEMBL1921269 | 0.64 | ACHE (0.44) | SMN1; SMN2ADORA2ABLMALDH1A1PDPK1 | |
| Dezaguanine SCHEMBL29384550 | 0.64 | PNP (0.53) | SMN1; SMN2ADORA2ABLMALDH1A1PDPK1 | |
| SCHEMBL1415174 | 0.64 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1PDPK1KDM4AKDM4B | |
| SCHEMBL2473003 | 0.64 | ALDH1A1 (0.64) | SMN1; SMN2ADORA2ALMNATSHRSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397142-B1 | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2022-07-27 | — | — | EP | claimed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | claimed |
| EP-4104838-A1 | Use of DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-2397142-B1 | Use of DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2022-07-27 | — | — | EP | disclosed |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| US-9975891-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975891-B2 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-23 | — | — | US | disclosed |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-23 | — | — | US | disclosed |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-6518271-B1 | 1H-imidazo[4,5-d]pyridazin-7-one, and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-11 | — | — | US | disclosed |
| US-6518271-B1 | 1H-imidazo[4,5-d]pyridazin-7-one, and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-11 | — | — | US | disclosed |
| EP-1140929-A4 | 1H-IMIDAZO 4,5-D]PYRIDAZIN-7-ONES, 3H-IMIDAZO 4,5-C]PYRIDIN-4-ONES AND CORRESPONDING THIONES AS CORTICOTROPIN RELEASING FACTOR (CRF) RECEPTOR LIGANDS | DU PONT PHARM CO (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1140929-A1 | 1H-IMIDAZO 4,5-D]PYRIDAZIN-7-ONES, 3H-IMIDAZO 4,5-C]PYRIDIN-4-ONES AND CORRESPONDING THIONES AS CORTICOTROPIN RELEASING FACTOR (CRF) RECEPTOR LIGANDS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6271380-B1 | TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC, NEUROLOGICAL DISORDERS AS WELL IMMUNOLOGICAL, CARDIOVASCULAR OR HEART-RELATED DISEASES AND COLONIC HYPERSENSITIVITY ASSOCIATED WITH PSYCHOPATHOLOGICAL DISTURBANCE AND STRESS. | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6271380-B1 | TREATING ANXIETY, DEPRESSION, AND OTHER PSYCHIATRIC, NEUROLOGICAL DISORDERS AS WELL IMMUNOLOGICAL, CARDIOVASCULAR OR HEART-RELATED DISEASES AND COLONIC HYPERSENSITIVITY ASSOCIATED WITH PSYCHOPATHOLOGICAL DISTURBANCE AND STRESS. | DUPONT PHARMACEUTICALS COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-2000039127-A1 | 1H-IMIDAZO[4,5-D]PYRIDAZIN-7-ONES, 3H-IMIDAZO[4,5-C]PYRIDIN-4-ONES AND CORRESPONDING THIONES AS CORTICOTROPIN RELEASING FACTOR (CRF) RECEPTOR LIGANDS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210691-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | SMN1; SMN2 3212/4885ADORA2A 4278/4885LMNA 925/4885 |
| US-20170050964-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | SMN1; SMN2 3271/4885ADORA2A 4227/4885LMNA 881/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | SMN1; SMN2 3212/4885ADORA2A 4278/4885LMNA 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.